J&J added that Consumer Health worldwide adjusted operational sales grew +11.3% mainly due to over-the-counter (OTC) products. J&J's Consumer Health segment sales in Q1 increased +7.4% Y/Y to $3.85B. ![]() Global sales of Remicade fell -26.5% Y/Y to $487M Imbruvica sales declined -20.3% Y/Y to $827M, while Zytiga's worldwide revenue slumped -54.5% Y/Y to $245M. J&J, noted that the growth in the Pharma division was partially offset by declines in sales of autoimmune diseases drug Remicade, blood cancer drug Imbruvica, and prostate cancer therapy Zytiga. ![]() Meanwhile, worldwide sales of Xarelto grew +13.7 to $578M.ĬOVID-19 Vaccine sales were only internationally and not in the U.S. Global sales of Carvykti in Q1 were $72M. Worldwide Erleada sales increased +35.6% to $542M. Global sales of Stelara, which treats immune-mediated inflammatory diseases, rose +6.8% Y/Y to ~$2.44B. Worldwide sales of Darzalex, developed with Genmab ( GMAB), grew +22 Y/Y to ~$2.26B. Revenue was also boosted by sales of COVID-19 Vaccine (). J&J said worldwide adjusted operational sales grew 7.2%, driven by blood cancer drug Darzalex, Stelara, prostate cancer therapy Erleada, CAR-T immunotherapy Carvykti and anticoagulant drug Xarelto. Sales from the Pharmaceutical division in Q1 increased +4.2% Y/Y to $13.41B. ![]() "Our first quarter results demonstrate strong performance across all three segments of our business and reflect the dedication of Johnson & Johnson colleagues around the world," said Chairman and CEO Joaquin Duato. Both top and bottom line beating analysts expectations. However, GAAP EPS was -$0.03, declining -101.6% Y/Y due to a special one-time charge. Q4 adjusted EPS grew marginally +0.4% Y/Y to $2.68. Johnson & Johnson ( NYSE: JNJ) is trading in the green premarket on Tuesday after Q1 results beat estimates and the company raised its FY23 outlook.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |